* Cantab Pharmaceuticals plc, of Cambridge, England,and New York-based Pfizer Inc. are collaborating inanimal-health applications of Cantab's Disc-Virustechnology, an antigen-delivery system. Cantab alreadyreceived $1.6 million in equity investments _ 800,000shares at $4 each _ and $2.4 million in license fees inthe potential $10 million deal.

* Bio-Technology General Corp., of Iselin, N.J., said itsIsraeli subsidiary is entitled to a compulsory license toCambridge, Mass.-based Biogen Inc.'s Israeli patent No.59007 relating to a genetically engineered hepatitis Bvaccine. The decision allows BTG to produce and marketits third-generation vaccine in Israel and perhaps othercountries, while paying a royalty to Biogen.

* Chiron Corp., of Emeryville, Calif., said the merger ofSan Diego-based Viagene Inc. into Chiron is expected tobe effective on Sept. 29, 1995.

* HemaSure Inc., a Marlborough, Mass., companydeveloping products to increase the safety of donatedblood and improve certain blood-related procedures,completed a public offering of 2.5 million shares at$18.50 apiece, grossing $46.25 million.

* Isis Pharmaceuticals Inc., of Carlsbad, Calif., said anindependent analysis confirmed earlier Phase I/II resultsshoeing its antisense drug, ISIS 2922, effectively haltedprogression of cytomegalovirus retinitis in AIDS patients.

* Paracelcian Inc., of Ithaca, N.Y., said it received cashand commitments exceeding $2.5 million fromundisclosed investors.

* Techniclone International Corp., of Tustin, Calif.,licensed rights to its tumor necrosis technologies (TNT)in China to Brilliance Shanghai Pharmaceuticals, ofChina. In exchange, Brilliance will fund $3 million inTNT research in the U.S.

(c) 1997 American Health Consultants. All rights reserved.